Corcept Therapeutics
CORT
193 hedge funds and large institutions have $1.2B invested in Corcept Therapeutics in 2019 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 67 increasing their positions, 62 reducing their positions, and 19 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
53% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 19
25% more capital invested
Capital invested by funds: $962M → $1.2B (+$241M)
5% more funds holding
Funds holding: 183 → 193 (+10)
8% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 62
6% more call options, than puts
Call options by funds: $4.41M | Put options by funds: $4.15M
0.24% less ownership
Funds ownership: 75.12% → 74.88% (-0.24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Parallel Advisors
San Francisco,
California
|
+$15.7M |
| 2 |
Renaissance Technologies
New York
|
+$11.5M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
+$6.57M |
| 4 |
Millennium Management
New York
|
+$6.34M |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$32.1M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$12.6M |
| 3 |
Morgan Stanley
New York
|
-$6.93M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$5.04M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.67M |
CORT Hedge Fund Activity: Q3 2019 in Review
193 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q3 2019, worth a combined $1.2B — up 25% from $962M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CORT positions and 19 closed out — a net gain of 10 holders — while 67 added to existing stakes and 62 trimmed.
The largest buyer was Parallel Advisors, adding an estimated $15.7M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $32.1M sold.
- 193 institutional investors held Corcept Therapeutics (CORT) as of Q3 2019, up from 183 in Q2 2019.
- Funds reported $1.2B of Corcept Therapeutics stock for Q3 2019, up 25% quarter-over-quarter.
- 29 funds opened new Corcept Therapeutics positions in Q3 2019 and 19 closed out, a net change of +10 holders.
- The largest Corcept Therapeutics buyer in Q3 2019 was Parallel Advisors, an estimated $15.7M added.
- The largest Corcept Therapeutics seller in Q3 2019 was Consonance Capital Management, an estimated $32.1M sold.
Based on aggregated 13F filings for Q3 2019.